Sandu Pharmaceuticals has informed that it enclosed Trading Approval Letter received from BSE pertaining to application made by Company in respect of the Trading of 8,50,326 equity shares of Rs 10 each to be issued at premium of Rs 10.69 bearing distinctive numbers from 8810665 to 9660990 issued to Promoter and Non-Promoters on a preferential basis pursuant to conversion of 8,50,326 warrants.
The above information is a part of company’s filings submitted to BSE.